Milestone Pharmaceuticals Inc. (MIST)

NASDAQ: MIST · IEX Real-Time Price · USD
+0.07 (2.31%)
At close: Sep 29, 2023, 4:00 PM
-0.15 (-4.84%)
After-hours: Sep 29, 2023, 4:13 PM EDT

Company Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.

The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans.

The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals logo
Country Canada
Founded 2003
Industry Biotechnology
Sector Healthcare
Employees 39
CEO Joseph G. Oliveto M.B.A.

Contact Details

1111 Boul. Dr.-frederik-philips, Ste 420
Montreal, A8 H4M 2X6
Quebec, Canada
Phone (514) 336-0444

Stock Details

Ticker Symbol MIST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001408443
CUSIP Number 59935V107
ISIN Number CA59935V1076
SIC Code 2834

Key Executives

Name Position
Joseph G. Oliveto M.B.A. Chief Executive Officer, President and Director
Amit Hasija Chief Financial Officer and Executive Vice President of Corporate Development
Dr. Philippe Douville M.B.A., Ph.D. Founder, Strategic Advisor and Member of Scientific Advisory Board
Jeff Nelson Chief Operating Officer
Roshan Girglani Vice President of Marketing
Kimberly Sheehan Vice President of Human Resources
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. Chief Medical Advisor and Member of the Scientific Advisory Board
Dr. Guy Rousseau SVice President of Regulatory Affairs and Quality Management
Lorenz Muller Chief Commercial Officer
Dr. David B. Bharucha FACC, M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Aug 10, 2023 8-K Current Report
Aug 10, 2023 10-Q Quarterly Report
Jun 9, 2023 8-K Current Report
May 31, 2023 424B5 Filing
May 31, 2023 10-K/A [Amend] Annual report
May 26, 2023 EFFECT Notice of Effectiveness
May 15, 2023 S-3 Registration statement under Securities Act of 1933
May 11, 2023 8-K Current Report
May 11, 2023 10-Q Quarterly Report
Apr 28, 2023 S-8 Securities to be offered to employees in employee benefit plans